No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PFE240712C25500
- 3.50
- +0.61+21.11%
15min DelayClose Jul 12 16:00 ET
3.50High3.50Low
3.50Open2.89Pre Close162 Volume164 Open Interest25.50Strike Price56.70KTurnover1203.07%IV0.28%PremiumJul 12, 2024Expiry Date3.42Intrinsic Value100Multiplier-1DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.8613Delta0.0623Gamma7.85Leverage Ratio-10.3065Theta0.0000Rho6.76Eff Leverage0.0007Vega
Intraday
- 5D
- Daily
News
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Goldman Sachs Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $31
Goldman Sachs analyst Chris Shibutani maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 44.9% and a
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Consumer price index data this week provided encouraging signs that American inflation is moving ever closer to the Federal Reserve's much-discussed 2% target.This fueled speculation about interest
Pfizer Options Spot-On: On July 12th, 180.09K Contracts Were Traded, With 2.9 Million Open Interest
On July 12th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 180.09K options for the day, of which put options accounted for 33.57% of the total transactions, and
Unusual Options Activity: RDDT, GXO and Others Attract Market Bets, RDDT V/OI Ratio Reaches 200.2
EST Jul 12th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
What the 2000's Tech Bubble Says About Today's Suspected Rotation - Analyst
Comments
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
Big potiental for Russell 2000, REITs & Bond markets in second half year of 2024.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
loading...
13
3
Morning Movers
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
39
6
$Pfizer(PFE.US$Pfizer Moves Forward With Once-Daily Weight Loss Pill
Read more